Nasal high flow oxygen therapy in patients with COPD reduces respiratory rate and tissue carbon dioxide while increasing tidal and end-expiratory lung volumes: a randomised crossover trial
John F Fraser, Amy J Spooner, Kimble R Dunster, Chris M Anstey, Amanda Corley, John F Fraser, Amy J Spooner, Kimble R Dunster, Chris M Anstey, Amanda Corley
Abstract
Patients with COPD using long-term oxygen therapy (LTOT) over 15 h per day have improved outcomes. As inhalation of dry cold gas is detrimental to mucociliary clearance, humidified nasal high flow (NHF) oxygen may reduce frequency of exacerbations, while improving lung function and quality of life in this cohort. In this randomised crossover study, we assessed short-term physiological responses to NHF therapy in 30 males chronically treated with LTOT. LTOT (2-4 L/min) through nasal cannula was compared with NHF at 30 L/min from an AIRVO through an Optiflow nasal interface with entrained supplemental oxygen. Comparing NHF with LTOT: transcutaneous carbon dioxide (TcCO2) (43.3 vs 46.7 mm Hg, p<0.001), transcutaneous oxygen (TcO2) (97.1 vs 101.2 mm Hg, p=0.01), I:E ratio (0.75 vs 0.86, p=0.02) and respiratory rate (RR) (15.4 vs 19.2 bpm, p<0.001) were lower; and tidal volume (Vt) (0.50 vs 0.40, p=0.003) and end-expiratory lung volume (EELV) (174% vs 113%, p<0.001) were higher. EELV is expressed as relative change from baseline (%Δ). Subjective dyspnoea and interface comfort favoured LTOT. NHF decreased TcCO2, I:E ratio and RR, with a concurrent increase in EELV and Vt compared with LTOT. This demonstrates a potential mechanistic rationale behind the improved outcomes observed in long-term treatment with NHF in oxygen-dependent patients.
Trial registration number: ACTRN12613000028707.
Keywords: COPD Exacerbations; Long Term Oxygen Therapy (LTOT); Non invasive ventilation.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Figures
References
- Kent BD, Mitchell PD, McNicholas WT. Hypoxemia in patients with COPD: cause, effects, and disease progression. Int J Chron Obstruct Pulmon Dis 2011;6:199–208. 10.2147/COPD.S10611
- Parke RL, McGuinness SP. Pressures delivered by nasal high flow oxygen during all phases of the respiratory cycle. Respir Care 2013;58:1621–4. 10.4187/respcare.02358
- Corley A, Caruana LR, Barnett AG, et al. . Oxygen delivery through high-flow nasal cannulae increase end-expiratory lung volume and reduce respiratory rate in post-cardiac surgical patients. Br J Anaesth 2011;107:998–1004. 10.1093/bja/aer265
- Dysart K, Miller TL, Wolfson MR, et al. . Research in high flow therapy: mechanisms of action. Respir Med 2009;103:1400–5. 10.1016/j.rmed.2009.04.007
- Chatila W, Nugent T, Vance G, et al. . The effects of high-flow vs low-flow oxygen on exercise in advanced obstructive airways disease. Chest 2004;126:1108–15. 10.1378/chest.126.4.1108
- Okuda M, Kashio M, Tanaka N, et al. . Nasal high-flow oxygen therapy system for improving sleep-related hypoventilation in chronic obstructive pulmonary disease: a case report. J Med Case Rep 2014;8:341 10.1186/1752-1947-8-341
- Bräunlich J, Beyer D, Mai D, et al. . Effects of nasal high flow on ventilation in volunteers, COPD and idiopathic pulmonary fibrosis patients. Respiration 2013;85:319–25. 10.1159/000342027
- Stéphan F, Barrucand B, Petit P, et al. . High-flow nasal oxygen vs noninvasive positive airway pressure in hypoxemic patients after cardiothoracic surgery. A randomized clinical trial. JAMA 2015;313:2331–9. 10.1001/jama.2015.5213
- Frat JP, Thille AW, Mercat A, et al. . High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med 2015;372:2185–96. 10.1056/NEJMoa1503326
- Rea H, McAuley S, Jayaram L, et al. . The clinical utility of long-term humidification therapy in chronic airways disease. Respir Med 2010;104:525–33. 10.1016/j.rmed.2009.12.016
Source: PubMed